Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.

Cancer journal (Sudbury, Mass.) - 1 Jan 2000

Desilets Antoine, Ho Alan L

Abstract excerpt

ABSTRACT: HRAS mutations define a unique biologic subset of head and neck squamous cell carcinoma. Oncogenic HRAS is uniquely dependent on posttranslational farnesylation for membrane localization and activation of downstream signaling. Tipifarnib, a farnesyltransferase inhibitor, demonstrated encouraging antitumor activity for HRAS mutant head and neck squamous cell carcinoma and modest activity for HRAS mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Products
Share to Cell Line, Tumor
Share to Farnesyltranstransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Head and Neck Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Squamous Cell Carcinoma of Head and Neck

Source

Identifiers

PMID: 36165724
DOI: 10.1097/PPO.0000000000000616

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.PMID 36165724Read ↗

Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.Semantic proximity Read ↗

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Molecular Aspects of Head and Neck Cancer Therapy.Semantic proximity Read ↗

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcomaSemantic proximity Read ↗

Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Semantic proximity Read ↗

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.Semantic proximity Read ↗

Molecular pathways in head and neck cancer: EGFR, PI3K, and more.Semantic proximity Read ↗

Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors.Semantic proximity Read ↗

The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinomaSemantic proximity Read ↗

PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical dataSemantic proximity Read ↗

Pharmacologic inhibition of ataxia telangiectasia and Rad3‐related (ATR) in the treatment of head and neck squamous cell carcinomaSemantic proximity Read ↗

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.